Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Icon ( (ICLR) ) has issued an update.
On January 14, 2025, ICON plc announced its financial guidance for the year ending December 31, 2025. The company projects revenue in the range of $8,050 – $8,650 million for 2025, representing a slight growth of about 1% compared to the previous year, with adjusted earnings per share expected to remain flat. The announcement highlighted the impact of dynamic market conditions, including conservative spending by biopharma customers, but also noted that strategic partnerships are anticipated to support growth throughout the year. ICON’s Q4 2024 stock repurchase activity amounted to $400 million, totaling $500 million for the year, as part of its ongoing efforts to manage the business environment effectively.
More about Icon
ICON plc is a world-leading healthcare intelligence and clinical research organization that offers outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. Headquartered in Dublin, Ireland, the company employs approximately 42,250 employees across 106 locations in 55 countries, advancing clinical research from molecule to medicine.
YTD Price Performance: 2.52%
Average Trading Volume: 1,347,266
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $18.02B
For detailed information about ICLR stock, go to TipRanks’ Stock Analysis page.
